FindTrial
Sign In

Multi-epitope Folate Receptor Alpha Peptide Vaccine

BIOLOGICAL2 trials

Sponsors

Mayo Clinic, Academic and Community Cancer Research United

Conditions

Bilateral Breast CarcinomaBreast Inflammatory CarcinomaRecurrent Breast CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaStage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7

Phase 1

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
CompletedNCT01606241
Mayo ClinicRecurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma +24
Start: 2012-07-24End: 2018-03-09Target: 24Updated: 2024-08-21

Phase 2

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Active, not recruitingNCT03012100
Academic and Community Cancer Research UnitedBilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7 +9
Start: 2017-03-31End: 2026-07-31Updated: 2026-06-30

Related Papers

A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.
Journal of Clinical Oncology2015-05-209 citations